← All candidates
Six insider buys in the last year — $171.6K in all.
37 filings on record.
ALTAltimmune, Inc.
NasdaqGM · Healthcare · $636.07M
$3.27
-0.61% · Sep 11
Six insider buys in the last year — $171.6K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 6 buys◆ 9 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what ALT ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$636.07M
Float
164.4M
85% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
20518.5
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Durso Jerome Benedict
Bought $51.6K on Dec 22 — 12,500 sh @ $4.13, held direct, 100% of their stake.
0 of 1 position beat the S&P
Director
Gill John
Bought $51.2K on Dec 23 — 12,500 sh @ $4.10, held direct, 100% of their stake.
0 of 1 position beat the S&P
Director
Pisano Wayne
Bought $20.4K on Jan 8 — 5,000 sh @ $4.08, held direct, 37% of their stake.
0 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
32 more transactions on Pro →Context
Wall St
$17.22 avg target
+426.7% vs today · 9 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 5 quarters beat
Q2 '26−$0.12 act+$0.01
Q1 '26−$0.18 act+$0.07
Q4 '25−$0.27 act−$0.03
Q3 '25−$0.21 act+$0.06
Coverage
Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics MarketInsider Monkey · 07-05Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerZacks · 06-26Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?Insider Monkey · 06-24Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic DataInsider Monkey · 06-17
The file stays open
37 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice